Eiry Wyn Roberts
Net Worth

Last updated:

What is Eiry Wyn Roberts net worth?

The estimated net worth of Dr. Eiry Wyn Roberts is at least $23,409,524 as of 8 Nov 2024. He owns shares worth $3,149,722 as insider, has earned $15,172,162 from insider trading and has received compensation worth at least $5,087,640 in Neurocrine Biosciences, Inc..

What is the salary of Eiry Wyn Roberts?

Dr. Eiry Wyn Roberts salary is $847,940 per year as Chief Medical Officer in Neurocrine Biosciences, Inc..

How old is Eiry Wyn Roberts?

Dr. Eiry Wyn Roberts is 61 years old, born in 1964.

What stocks does Eiry Wyn Roberts currently own?

As insider, Dr. Eiry Wyn Roberts owns shares in one company:

Company Title Shares Price per share Total value
Neurocrine Biosciences, Inc. (NBIX) Chief Medical Officer 23,716 $132.81 $3,149,722

What does Neurocrine Biosciences, Inc. do?

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Eiry Wyn Roberts insider trading

Neurocrine Biosciences, Inc.

Dr. Eiry Wyn Roberts has made 29 insider trades between 2019-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 50,497 units of NBIX stock on 7 Dec 2023. As of 8 Nov 2024 he still owns at least 23,716 units of NBIX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 971 $102.9 $99,916
Option
Incentive Stock Option 7,344 $87.25 $640,786
Option
Common Stock 5,140 $77.81 $399,943
Option
Common Stock 1,233 $81.05 $99,935
Option
Common Stock 1 $79.02 $79
Option
Incentive Stock Option 1 $79.02 $79
Sale
Common Stock 1,114 $132.96 $148,122
Sale
Common Stock 980 $134.21 $131,522
Sale
Common Stock 1,121 $142.24 $159,447
Sale
Common Stock 1,457 $140.79 $205,132
Sale
Common Stock 10,000 $126.75 $1,267,450
Option
Common Stock 6,947 $81.05 $563,054
Option
Common Stock 6,978 $81.05 $565,567
Option
Non-Qualified Stock Option 6,947 $81.05 $563,054
Option
Non-Qualified Stock Option 6,978 $81.05 $565,567
Sale
Common Stock 13,925 $120.31 $1,675,247
Option
Non-Qualified Stock Option 200 $81.05 $16,210
Option
Common Stock 100 $81.05 $8,105
Sale
Common Stock 300 $120.08 $36,023
Option
Non-Qualified Stock Option 100 $81.05 $8,105
Option
Common Stock 200 $81.05 $16,210
Option
Non-Qualified Stock Option 14,140 $79.02 $1,117,343
Option
Common Stock 38,722 $77.81 $3,012,959
Sale
Common Stock 50,497 $120.37 $6,078,475
Option
Common Stock 11,775 $81.05 $954,364
Option
Common Stock 14,140 $79.02 $1,117,343
Option
Non-Qualified Stock Option 38,722 $77.81 $3,012,959
Option
Non-Qualified Stock Option 11,775 $81.05 $954,364
Option
Non-Qualified Stock Option 12,742 $77.81 $991,455
Option
Common Stock 12,742 $77.81 $991,455
Sale
Common Stock 8,396 $120.03 $1,007,780
Option
Common Stock 8,396 $77.81 $653,293
Option
Non-Qualified Stock Option 8,396 $77.81 $653,293
Sale
Common Stock 3,198 $107.38 $343,388
Sale
Common Stock 14,400 $103.48 $1,490,054
Sale
Common Stock 980 $104.16 $102,072
Sale
Common Stock 1,623 $102.35 $166,114
Sale
Common Stock 12,801 $102.41 $1,310,925
Sale
Common Stock 1,121 $105.8 $118,602
Sale
Common Stock 1,457 $109.99 $160,254
Sale
Common Stock 980 $79.52 $77,931
Sale
Common Stock 1,121 $80.8 $90,575
Sale
Common Stock 1,623 $80.77 $131,086
Sale
Common Stock 2,632 $74.5 $196,087
Sale
Common Stock 2,363 $116.75 $275,876
Sale
Common Stock 2,632 N/A N/A
Sale
Common Stock 2,257 N/A N/A
Sale
Common Stock 2,257 N/A N/A
Option
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Non-Qualified Stock Option 5,000 N/A N/A
Sale
Common Stock 1,934 N/A N/A
Sale
Common Stock 1,623 N/A N/A
Sale
Common Stock 2,632 N/A N/A
Sale
Common Stock 1,857 N/A N/A

Neurocrine Biosciences key executives

Neurocrine Biosciences, Inc. executives and other stock owners filed with the SEC: